REGN197 has demonstrated efficacy and an acceptable safety profile in the treatment of follicular lymphoma, diffuse large B-cell lymphoma and other B cell non-Hodgkin lymphoma subtypes. Rajat Bannerji, MD, PhD, Rutgers Cancer institute of New Jersey, NJ, discusses this at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.